BPG is committed to discovery and dissemination of knowledge
Articles Published Processes Featured Articles Journals Submit a Manuscript
Cited by in CrossRef
For: Nadinskaia M, Maevskaya M, Ivashkin V, Kodzoeva Kh, Pirogova I, Chesnokov E, Nersesov A, Kaibullayeva J, Konysbekova A, Raissova A, Khamrabaeva F, Zueva E. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2021; 27(10): 959-975 [PMID: 33776366 DOI: 10.3748/wjg.v27.i10.959]
URL: https://www.wjgnet.com/1007-9327/full/v27/i10/959.htm
(394) (430) (0) (0) (33) (2) (19984) (70)
Number Citing Articles
1
志宇 高. Research Progress on the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease. Advances in Clinical Medicine 2024; 14(04) doi: 10.12677/acm.2024.1441142
2
Wenkang Gao, Zhonglin Li, Huikuan Chu, Hang Yuan, Lilin Hu, Lin Yao, Li Zhang, Weijun Wang, Rong Lin, Ling Yang. Pharmacotherapy for Liver Cirrhosis and Its Complications. 2022;  doi: 10.1007/978-981-19-2615-0_6
3
Yulia V. Kotovskaya. Non-alcoholic fatty liver disease and cardiovascular risks: A review. Consilium Medicum 2023; 25(4) doi: 10.26442/20751753.2023.4.202275
4
Rafał Frankowski, Mateusz Kobierecki, Andrzej Wittczak, Monika Różycka-Kosmalska, Tadeusz Pietras, Kasper Sipowicz, Marcin Kosmalski. Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, and Metabolic Repercussions: The Vicious Cycle and Its Interplay with Inflammation. International Journal of Molecular Sciences 2023; 24(11) doi: 10.3390/ijms24119677
5
Elizaveta Vinogradova, Nurislam Mukhanbetzhanov, Madiyar Nurgaziyev, Zharkyn Jarmukhanov, Rakhilya Aipova, Aliya Sailybayeva, Makhabbat Bekbossynova, Samat Kozhakhmetov, Almagul Kushugulova, Vanni Bucci. Impact of urbanization on gut microbiome mosaics across geographic and dietary contexts. mSystems 2024; 9(10) doi: 10.1128/msystems.00585-24
6
A. O. Bueverov. Hepatobiliary continuum: non-alcoholic fatty liver disease, cholelithiasis ... what else?. Meditsinskiy sovet = Medical Council 2021; (15) doi: 10.21518/2079-701X-2021-15-68-76
7
E.E. Mulyukova, E.L. Novikova, I.A. Skirdov, K.S. Usmanova, N.V. Yusifzade. Pharmacotherapy of the metabolically associated fatty liver disease. Russian Journal of Preventive Medicine 2025; 28(10) doi: 10.17116/profmed202528101103
8
Omar Hegazi, Samer Alalalmeh, Moyad Shahwan, Ammar Jairoun, Mansour Alourfi, Ghfran Bokhari, Abdullah Alkhattabi, Saeed Alsharif, Mohannad Aljehani, Abdulmalik Alsabban, Mohammad Almtrafi, Ysear Zakri, Abdullah AlMahmoud, Khalid Alghamdi, Ahmed Ashour, Nasser Alorfi. Exploring Promising Therapies for Non-Alcoholic Fatty Liver Disease: A ClinicalTrials.gov Analysis. Diabetes, Metabolic Syndrome and Obesity 2024;  doi: 10.2147/DMSO.S448476
9
Dongjie Wu, Jing Liu, Ziwei Guo, Liang Wang, Ziang Yao, Qingjuan Wu, Yanping Lu, Wenliang Lv. Natural bioactive compounds reprogram bile acid metabolism in MAFLD: Multi-target mechanisms and therapeutic implications. International Immunopharmacology 2025; 157 doi: 10.1016/j.intimp.2025.114708
10
Norio Akuta, Tomomi Kogiso, Kenichi Ikejima, Motoyuki Otsuka, Takumi Kawaguchi, Miwa Kawanaka, Hirokazu Takahashi, Nobuharu Tamaki, Hayato Nakagawa, Hayato Hikita, Hideki Fujii, Kanji Yamaguchi, Masato Yoneda, Kazuyoshi Kon, Akira Uchiyama, Yuya Seko, Sadatsugu Sakane, Ryuta Shigefuku, Naoto Fujiwara, Michihiro Iwaki, Takashi Kobayashi, Takuya Adachi, Yasuto Takeuchi, Tsubasa Tsutsumi, Dan Nakano, Kaoru Shibayama, Noriyo Urata, Hisamitsu Miyaaki, Hidekatsu Kuroda, Masahiro Koseki, Hirohito Sone, Yasuhiro Matsubayashi, Keisuke Kakisaka, Atsushi Takai, Kazuo Notsumata, Masataka Seike, Yoshiyuki Takei, Yoshifumi Takeyama, Susumu Eguchi, Sumio Watanabe, Hajime Isomoto, Hiroshi Yotsuyanagi, Takao Itoi, Tetsuo Takehara, Satoshi Mochida. Evidence‐Based Clinical Practice Guidelines for Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) 2026. Hepatology Research 2026; 56(6) doi: 10.1111/hepr.70188
11
Marina V. Maevskaya, Yulia V. Kotovskaya, Vladimir T. Ivashkin, Olga N. Tkacheva, Ekaterina A. Troshina, Marina V. Shestakova, Valeriy V. Breder, Natalia I. Geyvandova, Vladimir L. Doshchitsin, Ekaterina N. Dudinskaya, Ekaterina V. Ershova, Khava B. Kodzoeva, Ksenia A. Komshilova, Natalia V. Korochanskaya, Alexander Yu. Mayorov, Ekaterina E. Mishina, Maria Yu. Nadinskaya, Igor G. Nikitin, Nana V. Pogosova, Aida I. Tarzimanova, Minara Sh. Shamkhalova. The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. Terapevticheskii arkhiv 2022; 94(2) doi: 10.26442/00403660.2022.02.201363
12
V. T. Ivashkin, M. V. Maevskaya, M. S. Zharkova, Yu. V. Kotovskaya, O. N. Tkacheva, E. A. Troshina, M. V. Shestakova, I. V. Maev, V. V. Breder, N. I. Gheivandova, V. L. Doshchitsin, E. N. Dudinskaya, E. V. Ershova, Kh. B. Kodzoeva, K. A. Komshilova, N. V. Korochanskaya, A. Yu. Mayorov, E. E. Mishina, M. Yu. Nadinskaya, I. G. Nikitin, N. V. Pogosova, A. I. Tarzimanova, M. Sh. Shamkhalova. Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology 2022; 32(4) doi: 10.22416/1382-4376-2022-32-4-104-140
13
Kazuki Kobayashi, Yoji Kishi, Takazumi Tsunenari, Naoto Yonamine, Yasuhiro Takihata, Akiko Nakazawa, Mikiya Takao, Takahiro Einama, Hironori Tsujimoto, Hideki Ueno. Risk of hepatic steatosis with the preoperative treatment of pancreatic cancer and the short-term postoperative outcomes. Surgery Today 2025; 55(2) doi: 10.1007/s00595-024-02895-x
14
Prachi Agnihotri, Mohd Saquib, Lovely Joshi, Swati Malik, Debolina Chakraborty, Ashish Sarkar, Uma Kumar, Sagarika Biswas. Integrative metabolomic-proteomic analysis uncovers a new therapeutic approach in targeting rheumatoid arthritis. Arthritis Research & Therapy 2024; 26(1) doi: 10.1186/s13075-024-03429-z
15
Yousef S. Mohamed, Dina S. El-Kafrawy, Magdy M. Abdel-Khalek, Amira H. Abo-Gharam. Bridging MOE with eco-friendly chromatographic analyses of metformin and ursodeoxycholic acid with their official impurities: Multi-metric sustainability assessment. Sustainable Chemistry and Pharmacy 2026; 53 doi: 10.1016/j.scp.2026.102553
16
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, Marlene Chakhtoura, Michael A. Hill, Dimitri P. Mikhailidis, Christos S. Mantzoros. Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies. Pharmacological Reviews 2024; 76(3) doi: 10.1124/pharmrev.123.001087
17
Na Li, Cheng Zhao, Pingnan Zhang, Songting Wu, Xiaotan Dou, Saifei Xu, Xiaoqi Zhang, Chunyan Peng, Ying Xie, Shuling Huang, Lin Zhou, Yonghua Shen, Lei Wang, Jinglin Wang, Chenggong Yu. The role of gut microbiota associated metabolites in digestive disorders. Engineered Regeneration 2024; 5(2) doi: 10.1016/j.engreg.2024.04.003
18
M. V. Maevskaya, S. V. Okovityi, I. G. Bakulin, A. S. Bidzhiev, D. V. Glushenkov, O. Yu. Gurova, A. Yu. Gorshkov, V. A. Zhakipbekova, O. Yu. Zolnikova, M. M. Karimov, Yu. V. Kotovskaya, I. V. Maev, R. V. Maslennikov, M. Yu. Nadinskaia, M. F. Osipenko, K. L. Raikhelson, B. P. Sultanova, O. N. Tkacheva, E. A. Troshina, Z. Yu. Khalimova, G. A. Khamidullaeva, A. F. Sheptulina, E. N. Shirokova, O. M. Drapkina, V. T. Ivashkin. Results of the Interdisciplinary International Expert Council on Addressing the Management of Patients with Non-Alcoholic (Metabolic Dysfunction- Associated) Fatty Liver Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology 2026; 36(3) doi: 10.22416/1382-4376-2026-36-3-7-20
19
Zhaoxi Zhang, Alice Pik-Shan Kong, Vincent Wai-Sun Wong, Hannah Xiaoyan Hui. Intermittent fasting and metabolic dysfunction-associated steatotic liver disease: the potential role of the gut-liver axis. Cell & Bioscience 2025; 15(1) doi: 10.1186/s13578-025-01406-w
20
Xiaokun Li, Zhiheng Rao, Wenhao Hu, Weiqin Lu, Yongde Luo. Treating metabolic dysfunction‐associated steatohepatitis: The fat‐trimming FGF21 approach. Obesity Reviews 2025; 26(3) doi: 10.1111/obr.13861
21
Pervej Alom Barbhuiya, Ameena Ahmed, Partha Pratim Dutta, Saikat Sen, Manash Pratim Pathak. Mitigating Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): The Role of Bioactive Phytoconstituents in Indian Culinary Spices. Current Nutrition Reports 2025; 14(1) doi: 10.1007/s13668-024-00598-w
22
Jiahong Ai, Xingwei Li, Yurong Zhang, Fangjun Huo, Caixia Yin. Esterase-activated fluorescent prodrug for targeted early diagnosis and treatment of hepatic fibrosis. Science China Chemistry 2026; 69(1) doi: 10.1007/s11426-025-2731-6
23
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, Shan Liu, Tatsunori Miyata, Qiaoling Song, Qingda Wei, Chenyang Zhao, Chunhua Lin, Jinbo Yang. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduction and Targeted Therapy 2022; 7(1) doi: 10.1038/s41392-022-01119-3
24
M. V. Maevskay. Ursodeoxycholic acid: unique properties and clinical applications. Meditsinskiy sovet = Medical Council 2023; (8) doi: 10.21518/ms2023-136
25
A. S. Safaryan. Role of bile acids in atherogenesis: review. Cardiovascular Therapy and Prevention 2024; 23(10) doi: 10.15829/1728-8800-2024-4126
26
Qian Huai, Xiaolei Li, Hua Wang, Shi Yin. The Gut-Liver Axis in Metabolic Dysfunction-Associated Steatotic Liver Disease and Associated Hepatocellular Carcinoma: Pathogenesis and Therapeutic Interventions. The American Journal of Pathology 2026;  doi: 10.1016/j.ajpath.2026.09.004
27
B. Reilly-O’Donnell, E. Ferraro, R. Tikhomirov, R. Nunez-Toldra, A. Shchendrygina, L. Patel, Y. Wu, A. L. Mitchell, A. Endo, L. Adorini, R. A. Chowdhury, P. K. Srivastava, F. S. Ng, C. Terracciano, C. Williamson, J. Gorelik. Protective effect of UDCA against IL-11- induced cardiac fibrosis is mediated by TGR5 signalling. Frontiers in Cardiovascular Medicine 2024; 11 doi: 10.3389/fcvm.2024.1430772
28
S. N. Mekhtiev, O. A. Mekhtievа, O. M. Berko. Current perspective on the problem of cholesterol polyps of the gallbladder in patients with nonalcoholic fatty liver disease. Meditsinskiy sovet = Medical Council 2022; (14) doi: 10.21518/2079-701X-2022-16-14-70-78
29
Liyan Wang, Jiali Xu, Ningning You, Li Shao, Zhenjie Zhuang, Lili Zhuo, Jing Liu, Junping Shi. Characteristics of intestinal flora in nonobese nonalcoholic fatty liver disease patients and the impact of ursodeoxycholic acid treatment on these features. Lipids 2024; 59(6) doi: 10.1002/lipd.12410
30
Alsu R. Khurmatullina, Dmitrii N. Andreev, Igor V. Maev, Andrey V. Zaborovsky, Yury A. Kucheryavyy, Petr A. Beliy, Philipp S. Sokolov. Efficacy of ursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease: an umbrella review of meta-analyses on liver enzymes. Frontiers in Medicine 2026; 13 doi: 10.3389/fmed.2026.1771830
31
Li Rong, Junyan Zou, Wei Ran, Xiaohong Qi, Yaokai Chen, Hongjuan Cui, Jinjun Guo. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Frontiers in Endocrinology 2023; 13 doi: 10.3389/fendo.2022.1087260
32
A. R. Khurmatullina, D. N. Andreev, I. V. Maev, Yu. A. Kucheryavyy, A. V. Zaborovskiy. Effect of ursodeoxycholic acid on changes in non-invasive calculated indices of steatosis and fibrosis in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. Meditsinskiy sovet = Medical Council 2026; (8) doi: 10.21518/ms2026-221
33
M. Imawari, M. Nagase, I. Yu. Torshin, O. A. Gromova. An open-label, controlled trial of the clinical effects of Laennec® in patients with nonalcoholic steatohepatitis or cirrhosis. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology 2023; 16(3) doi: 10.17749/2070-4909/farmakoekonomika.2023.206
34
Disha Dhar, Jessica Packer, Semina Michalopoulou, Joana Cruz, Claire Stansfield, Russell M. Viner, Oliver T. Mytton, Simon J. Russell. Assessing the evidence for health benefits of low-level weight loss: a systematic review. International Journal of Obesity 2025; 49(2) doi: 10.1038/s41366-024-01664-7
35
Han Fang, Rodrigo Rodrigues e-Lacerda, Nicole G Barra, Dana Kukje Zada, Nazli Robin, Alina Mehra, Jonathan D Schertzer. Postbiotic Impact on Host Metabolism and Immunity Provides Therapeutic Potential in Metabolic Disease. Endocrine Reviews 2025; 46(1) doi: 10.1210/endrev/bnae025
36
Mohammad Heiat, Mohammad Mahmudian, Sobhan Eisazadeh, Ramin Radmanesh, Mostafa Eslamimahmoudabadi, Mohamad Ali Abyazi. Comparison of the Safety and Efficacy of Newly-Developed Generic Ursodeoxycholic Acid (Cholicray<sup>®</sup>) and Ursophar<sup>®</sup> as Standard Drug in Patients with Non-alcoholic Fatty Liver Disease: A Phase IIa Double-Blind Randomized Controlled Clinical Trial. Hepatitis Monthly 2025; 25(1) doi: 10.5812/hepatmon-165095
37
Supriyo Ghosh, Amlan Jyoti Ghosh, Manab Deb Adhikari, Bipransh Kumar Tiwary, Tilak Saha. Probiotics for managing non-alcoholic fatty liver disease: efficacy and mechanistic insights. Journal of Diabetes & Metabolic Disorders 2026; 25(1) doi: 10.1007/s40200-026-01861-3
38
E. E. Mulyukova, E. L. Novikova, I. A. Skirdov, K. S. Usmanova, N. V. Yusifzade. Pharmacotherapy of metabolically associated fatty liver disease. Experimental and Clinical Gastroenterology 2026; (8) doi: 10.31146/1682-8658-ecg-240-8-156-163
39
Yuan Zhou, Ruoqi Li, Yingyi Zheng, Meiying Song, Shanshan Zhang, Yunxia Sun, Mengying Wei, Xiang Fan. Diosgenin Ameliorates Non-alcoholic Fatty Liver Disease by Modulating the Gut Microbiota and Related Lipid/Amino Acid Metabolism in High Fat Diet-Fed Rats. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.854790
40
Zi-Lin Ren, Chang-Xiang Li, Chong-Yang Ma, Dan Chen, Jia-Hui Chen, Wen-Xiu Xu, Cong-Ai Chen, Fa-Feng Cheng, Xue-Qian Wang. Linking Nonalcoholic Fatty Liver Disease and Brain Disease: Focusing on Bile Acid Signaling. International Journal of Molecular Sciences 2022; 23(21) doi: 10.3390/ijms232113045
41
Haoze Yang, Xuyao Zhang, Dan Zhou, Jing Zou, Lei Xu, Meihan Chen, Siyu Zhao, Jiaxuan Dai, Xiaoming Wang, Xi Du, Jia Liu, Yuhong Huang, Guixiang Pan. Dysregulation of the bile acid signaling network in non-alcoholic fatty liver disease: Mechanisms and a new paradigm of precision network pharmacology. Biochemical Pharmacology 2026; 252 doi: 10.1016/j.bcp.2026.118225
42
A Current Understanding of Bile Acids in Chronic Liver Disease. Journal of Clinical and Experimental Hepatology 2022; 12(1) doi: 10.1016/j.jceh.2021.08.017
43
Jinghan Jia, Shuyue Zhai, Tianqi Cai, Pingping Guo, Gangao Yang, Zukang Chang, Yongning Chen, Xinhua Song, Xueyao Lu, Le Chu, Fatao He, Maoyu Wu, Guangpeng Liu, Wenlong Sun. Rutin alleviates high-fat diet-induced MAFLD: insights from 16S rRNA sequencing, metabolome, network pharmacology and transcriptome analyses. Food Science and Human Wellness 2026; 15(1) doi: 10.26599/FSHW.2025.9250908
44
Ranko Škrbić, Tatjana Milivojac, Milkica Grabež, Ljiljana Amidžić, Zorislava Bajic, Tanja Sobot, Nebojša Mandić-Kovačević, Snežana Uletilović, Đorđe Đukanović, Milica Gajic Bojic, Sanja Jovičić, Maja Barudžija, Nataša Vojinović, Miloš P. Stojiljković, Dragan M. Djuric, Hani Al-Salami, Sergey Bolevich, Momir Mikov. Ursodeoxycholic Acid Attenuates Lipopolysaccharide-Induced Myocardial Injury by Inhibiting Oxidative Stress, Inflammation, and Apoptosis: The Interplay of Sirt1/Nrf2 and Akt/NF-κB Signaling Pathways. International Journal of Molecular Sciences 2026; 27(6) doi: 10.3390/ijms27062843
45
Nahum Méndez-Sánchez, Shreya C. Pal, Jacqueline Córdova-Gallardo. How far are we from an approved drug for nonalcoholic steatohepatitis?. Expert Opinion on Pharmacotherapy 2023; 24(9) doi: 10.1080/14656566.2023.2206953
46
Yafang Yang, Ligang Yang, Jiale Wu, Jing Hu, Min Wan, Jindi Bie, Jiaxin Li, Da Pan, Guiju Sun, Chao Yang. Optimal probiotic combinations for treating nonalcoholic fatty liver disease: A systematic review and network meta-analysis. Clinical Nutrition 2024; 43(6) doi: 10.1016/j.clnu.2024.04.004
47
R. M. Brekhunets, D. T. Dicheva, A. R. Khurmatullina, D. N. Andreev, A. K. Kulieva, O. E. Berezutskaya, N. L. Golovkina, I. V. Maev. Efficacy of combination therapy with lifestyle modification and ursodeoxycholic acid in patients with non-alcoholic fatty liver disease: Results of a prospective study. Meditsinskiy sovet = Medical Council 2026; (23) doi: 10.21518/ms2025-563
48
Xiu-Ping Bai, Ling-Yan Wei, Yu-Feng Han, Xiao-Jin Han, Feng Dong. Effects of ursodeoxycholic acid on blood glucose and related metabolic indexes in type 2 diabetes rats. Discover Endocrinology and Metabolism 2026; 2(1) doi: 10.1007/s44417-026-00024-5
49
V. T. Ivashkin, O. M. Drapkina, M. V. Maevskaya, K. L. Raikhelson, S. V. Okovityi, M. S. Zharkova, V. R. Grechishnikova, D. I. Abdulganieva, S. A. Alekseenko, M. D. Ardatskaya, I. G. Bakulin, N. V. Bakulina, P. O. Bogomolov, V. V. Breder, E. V. Vinnitskaya, N. I. Geyvandova, E. V. Golovanova, V. B. Grinevich, V. L. Doshchitsin, E. N. Dudinskaya, E. V. Ershova, K. B. Kodzoeva, I. V. Kozlova, K. A. Komshilova, Yu. V. Konev, N. V. Korochanskaya, Yu. V. Kotovskaya, Yu. A. Kravchuk, I. D. Loranskaya, I. V. Maev, A. I. Martynov, S. N. Mekhtiev, E. E. Mishina, M. Yu. Nadinskaia, I. G. Nikitin, M. F. Osipenko, O. D. Ostroumova, Ch. S. Pavlov, N. V. Pogosova, V. G. Radchenko, G. E. Roytberg, R. G. Saifutdinov, A. A. Samsonov, P. V. Seliverstov, S. I. Sitkin, L. V. Tarasova, A. I. Tarzimanova, O. N. Tkacheva, E. I. Tkachenko, E. A. Troshina, S. V. Turkina, Yu. P. Uspenskiy, Yu. A. Fominykh, O. V. Khlynova, Yu. V. Tsyganova, M. Sh. Shamkhalova, O. O. Sharkhun, M. V. Shestakova. Clinical Guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Society for the Prevention of Non-Communicable Diseases, Russian Association of Endocrinologists, Russian Scientific Medical Society of Therapists, National Society of Preventive Cardiology, Russian Association of Gerontologists and Geriatricians on Non-Alcoholic Fatty Liver Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology 2025; 35(1) doi: 10.22416/1382-4376-2025-35-1-94-152
50
NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD): DISEASE MECHANISMS AND CONTEMPORARY THERAPEUTIC APPROACHES - A LITERATURE REVIEW. International Journal of Innovative Technologies in Social Science 2025; 2(3(47)) doi: 10.31435/ijitss.3(47).2025.3662
51
Seogsong Jeong, Woo-Young Shin, Yun Hwan Oh. Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma. Frontiers in Endocrinology 2023; 14 doi: 10.3389/fendo.2023.1150360
52
Anlu Wang, Baoyi Guan, He Zhang, Hao Xu. Danger-associated metabolites trigger metaflammation: A crowbar in cardiometabolic diseases. Pharmacological Research 2023; 198 doi: 10.1016/j.phrs.2023.106983
53
Shouer Lin, Pingping Wu, Youjia Wu, Liying Huang, Lingyi Huang. Screening and verification of target and molecular docking study of Pien-Tze-Huang in ameliorating alcoholic liver injury in rats. Journal of Pharmaceutical and Biomedical Analysis 2025; 253 doi: 10.1016/j.jpba.2024.116517
54
Norio Akuta, Tomomi Kogiso, Kenichi Ikejima, Motoyuki Otsuka, Takumi Kawaguchi, Miwa Kawanaka, Hirokazu Takahashi, Nobuharu Tamaki, Hayato Nakagawa, Hayato Hikita, Hideki Fujii, Kanji Yamaguchi, Masato Yoneda, Kazuyoshi Kon, Akira Uchiyama, Yuya Seko, Sadatsugu Sakane, Ryuta Shigefuku, Naoto Fujiwara, Michihiro Iwaki, Takashi Kobayashi, Takuya Adachi, Yasuto Takeuchi, Tsubasa Tsutsumi, Dan Nakano, Kaoru Shibayama, Noriyo Urata, Hisamitsu Miyaaki, Hidekatsu Kuroda, Masahiro Koseki, Hirohito Sone, Yasuhiro Matsubayashi, Keisuke Kakisaka, Atsushi Takai, Kazuo Notsumata, Masataka Seike, Yoshiyuki Takei, Yoshifumi Takeyama, Susumu Eguchi, Sumio Watanabe, Hajime Isomoto, Hiroshi Yotsuyanagi, Takao Itoi, Tetsuo Takehara, Satoshi Mochida. Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026. Journal of Gastroenterology 2026; 61(6) doi: 10.1007/s00535-026-02408-2
55
Ye Rin Park, Hae Lee Lee, Ji Ye Hyun, Jieun Choi, Ji Hyun Moon, Byung Yong Kim, Seung-Jo Yang, Je Hee Lee, Byoung Kook Kim, Tae-Sik Park, Ki Tae Suk, Do Yup Lee, Heenam Stanley Kim. Systemic multiomics evaluation of the therapeutic effect of Bacteroides species on liver cirrhosis in male mice . Microbiology Spectrum 2023; 11(6) doi: 10.1128/spectrum.05349-22
56
Marcin Kosmalski, Rafał Frankowski, Sylwia Ziółkowska, Monika Różycka-Kosmalska, Tadeusz Pietras. What’s New in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD). Journal of Clinical Medicine 2023; 12(5) doi: 10.3390/jcm12051852
57
T Milivojac, M Grabež, A Krivokuća, U Maličević, M Gajić Bojić, Đ Đukanović, S Uletilović, N Mandić-Kovačević, T Cvjetković, M Barudžija, N Vojinović, A Šmitran, Lj Amidžić, MP Stojiljković, M Čolić, M Mikov, R Škrbić. Ursodeoxycholic and chenodeoxycholic bile acids attenuate systemic and liver inflammation induced by lipopolysaccharide in rats. Molecular and Cellular Biochemistry 2025; 480(1) doi: 10.1007/s11010-024-04994-2
58
Chunye Zhang, Ming Yang. The Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma. Cancers 2021; 13(15) doi: 10.3390/cancers13153740
59
Tao Zhang, Yingli Nie, Jiliang Wang. The emerging significance of mitochondrial targeted strategies in NAFLD treatment. Life Sciences 2023; 329 doi: 10.1016/j.lfs.2023.121943
60
E. E. Zabotina, Yu. A. Khabarova, N. Yu. Stukova. Metabolic dysfunction associated steatotic liver disease in lean patients. Diagnostic and treatment challenges. Experimental and Clinical Gastroenterology 2025; (9) doi: 10.31146/1682-8658-ecg-229-9-96-109
61
Anastasiya M. Kaneva, Evgeny R. Bojko. Fatty liver index (FLI): more than a marker of hepatic steatosis. Journal of Physiology and Biochemistry 2024; 80(1) doi: 10.1007/s13105-023-00991-z
62
Jiali Rao, Xuefei Li, Yushuang Zhang, Juan Guo, Baomin Feng, Yujie Lu, Xiaoyao Ma. Magnoflorine Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Targeting the NDUFV1 Subunit of Complex I to Regulate the ROS/AMPK Signaling Pathway. Journal of Agricultural and Food Chemistry 2026;  doi: 10.1021/acs.jafc.6c05636
63
Xin Ding, Xu He, Bulang Tang, Tian Lan. Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies. Chinese Medicine 2024; 19(1) doi: 10.1186/s13020-024-00894-1
64
Qingyi Mao, Beibei Lin, Wenluo Zhang, Yu Zhang, Yu Zhang, Qian Cao, Mengque Xu. Understanding the role of ursodeoxycholic acid and gut microbiome in non-alcoholic fatty liver disease: current evidence and perspectives. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1371574
65
Dong Chen, Xinyu Li, Jinghao Fu, Yaohan Ma, Hanyue Jiang, Qiang Li. Clinical efficacy of Jiawei Yinchenhao decoction combined with ursodeoxycholic acid and probiotics in the management of nonalcoholic fatty liver disease. Arab Journal of Gastroenterology 2026; 27(2) doi: 10.1016/j.ajg.2026.01.007
66
Yue Yu, Jie Zheng, Jianqing She, Zuyi Yuan, Yue Wu. Effects of ursodeoxycholic acid on statin-induced impaired glucose tolerance: study protocol for a randomized controlled trial. BMJ Open 2026; 16(7) doi: 10.1136/bmjopen-2026-117417
67
Sevag Hamamah, Oana C. Iatcu, Mihai Covasa. Dietary Influences on Gut Microbiota and Their Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Nutrients 2024; 17(1) doi: 10.3390/nu17010143
68
Sahar H. Elhini, Engy A. Wahsh, Ahmed A. Elberry, Nadia F. El Ameen, Ahmed Abdelfadil Saedii, Shereen Mahmoud Refaie, Asmaa A. Elsayed, Hoda M. Rabea. The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients. Pharmaceuticals 2022; 15(12) doi: 10.3390/ph15121516
69
Qianqian Zhu, Chengde Su, Qiaoqiao Yao, Ting Yang, Yali Xu, Mingdan Li, Qian Liu, Yawen Luo, Ping Yang. The “viral–metabolic” interaction mechanisms and management challenges in chronic hepatitis B combined with metabolic dysfunction-associated fatty liver disease: from clinical evidence to an integrated multidisciplinary framework. Frontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1920121
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.